Yamada Taketo
Department of Pathology, School of Medicine, Keio University, Tokyo, Japan.
Keio J Med. 2011;60(2):37-46. doi: 10.2302/kjm.60.37.
Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.
自北里柴三郎和贝林发现“神奇子弹”血清疗法——有史以来首次将抗体用于治疗——已过去一百多年。八十多年后，对免疫球蛋白结构与功能的研究以及细胞和分子生物学的发展催生了单克隆抗体（MoAbs）的生产。自首个制备单克隆抗体的方法问世35年来，它们一直是蓬勃发展的生物技术和制药行业的核心。在此，我回顾了对挽救生命的医学产生重大影响的治疗性单克隆抗体的历史、发展及临床应用情况。
